Elevated SKP2 levels were also associated with PTEN loss resulting in poor patient outcome and PCa progression, while reduced SKP2 has been shown to decrease prostate tumorigenesis [25, 36, 37]. This evidence concerns the gene SKP2 and posterior cortical atrophy.